105 related articles for article (PubMed ID: 2543895)
21. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
22. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.
Kroon UB; Silfverstolpe G; Tengborn L
Thromb Haemost; 1994 Apr; 71(4):420-3. PubMed ID: 8052956
[TBL] [Abstract][Full Text] [Related]
23. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial).
Vesna A; Neli B
Maturitas; 2006 Feb; 53(3):282-98. PubMed ID: 16011883
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
Leodolter S; Sainz H; Moll-Schüler I; Mach R
Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of transdermal estradiol.
Judd H
Am J Obstet Gynecol; 1987 May; 156(5):1326-31. PubMed ID: 3034062
[TBL] [Abstract][Full Text] [Related]
26. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
[TBL] [Abstract][Full Text] [Related]
27. Menorest: a clinical overview.
Wren B
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
29. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
30. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
31. [Percutaneous estrogen therapy in the post-menopausal period].
Keller PJ
Schweiz Med Wochenschr; 1989 Jul; 119(29):999-1004. PubMed ID: 2678438
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience with a 7-day estrogen patch: principles and practice.
Notelovitz M
Gynecol Endocrinol; 1998 Aug; 12(4):248-58. PubMed ID: 9798134
[TBL] [Abstract][Full Text] [Related]
33. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period.
Haas S; Walsh B; Evans S; Krache M; Ravnikar V; Schiff I
Obstet Gynecol; 1988 May; 71(5):671-6. PubMed ID: 3357653
[TBL] [Abstract][Full Text] [Related]
34. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
35. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
36. [Splenopeptides for climacteric complaints. Comparison of ovarian stimulation with transdermal estradiol substitution].
Lauritzen C; Teucher T; Schmitz H
Arzneimittelforschung; 1995 Mar; 45(3):315-22. PubMed ID: 7741793
[TBL] [Abstract][Full Text] [Related]
37. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
38. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
40. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
Johnson SR; Ettinger B; Macer JL; Ensrud KE; Quan J; Grady D
Obstet Gynecol; 2005 Apr; 105(4):779-87. PubMed ID: 15802405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
